FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009367105> ?p ?o ?g. }

• W2009367105 endingPage "21" @default.
• W2009367105 startingPage "15" @default.
• W2009367105 abstract "Abstract Psoriasis is a chronic inflammatory skin condition that affects approximately 2% of the population. Up to 50% of patients with psoriasis have concurrent nail psoriasis, with a lifetime incidence of 80% to 90%. Up to 30% of patients with skin psoriasis also have psoriatic arthritis (PsA) and of these, approximately 80% have nail disease. However, nail involvement is often overlooked by physicians, despite the significant burden it places on patients as a result of functional impairment of manual dexterity, pain and psychological stress. Affected nail plates often thicken and crumble, and because they are very visible, patients are usually concerned about the appearance of their nails, often causing them to avoid normal day‐to‐day activities (including work). In the longer‐term, nail involvement may be a signal of a more severe form of psoriasis or a precursor of PsA. Conventional treatment of nail psoriasis is generally considered inconvenient by patients, and it is limited by adverse effects and often a reduction in efficacy over time. There is also a lack of controlled clinical trials’ data and no consistent treatment approach has been advocated. Recently, the effects of biologic agents targeted against tumour necrosis factor alpha (TNFα) on nail psoriasis have been investigated. The multicentre, double‐blind EXPRESS [European Infliximab for Psoriasis (Remicade) Efficacy and Safety Study] trial revealed that infliximab 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks significantly improved nail psoriasis, evaluated using the Nail Psoriasis Severity Index (NAPSI) in 378 patients with moderate to severe psoriasis. Significant improvement was reported as early as week 10, and at week 50 full nail clearance was evident in 45% of patients receiving infliximab. There is also evidence from small studies that infliximab significantly improves nail lesions and quality of life in patients with nail psoriasis. There is a need for improving the awareness of nail psoriasis and its impact on patients’ quality of life. Moreover, the potential role for nail involvement as a link between psoriasis and PsA underlines its importance and the need for effective management. Infliximab has been shown to improve psoriatic nail lesions and quality of life, and it should be considered as one of the most appropriate available treatment options for the many patients with this distressing condition. Conflicts of interest None declared." @default.
• W2009367105 created "2016-06-24" @default.
• W2009367105 creator A5000572878 @default.
• W2009367105 date "2009-08-11" @default.
• W2009367105 modified "2023-09-23" @default.
• W2009367105 title "Approach to managing patients with nail psoriasis" @default.
• W2009367105 cites W1983284744 @default.
• W2009367105 cites W1993434356 @default.
• W2009367105 cites W2002734145 @default.
• W2009367105 cites W2007237234 @default.
• W2009367105 cites W2014111735 @default.
• W2009367105 cites W2020776325 @default.
• W2009367105 cites W2029421701 @default.
• W2009367105 cites W2029499820 @default.
• W2009367105 cites W2031738399 @default.
• W2009367105 cites W2035059473 @default.
• W2009367105 cites W2035968875 @default.
• W2009367105 cites W2052408898 @default.
• W2009367105 cites W2056840860 @default.
• W2009367105 cites W2066384476 @default.
• W2009367105 cites W2080165152 @default.
• W2009367105 cites W2081962645 @default.
• W2009367105 cites W2082817348 @default.
• W2009367105 cites W2086334974 @default.
• W2009367105 cites W2087232027 @default.
• W2009367105 cites W2095169919 @default.
• W2009367105 cites W2096991001 @default.
• W2009367105 cites W2101695974 @default.
• W2009367105 cites W2109406330 @default.
• W2009367105 cites W2116232969 @default.
• W2009367105 cites W2120422600 @default.
• W2009367105 cites W2126993279 @default.
• W2009367105 cites W2139384965 @default.
• W2009367105 cites W2139788459 @default.
• W2009367105 cites W2154464476 @default.
• W2009367105 cites W2172257129 @default.
• W2009367105 cites W4249483860 @default.
• W2009367105 doi "https://doi.org/10.1111/j.1468-3083.2009.03364.x" @default.
• W2009367105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19686381" @default.
• W2009367105 hasPublicationYear "2009" @default.
• W2009367105 type Work @default.
• W2009367105 sameAs 2009367105 @default.
• W2009367105 citedByCount "97" @default.
• W2009367105 countsByYear W20093671052012 @default.
• W2009367105 countsByYear W20093671052013 @default.
• W2009367105 countsByYear W20093671052014 @default.
• W2009367105 countsByYear W20093671052015 @default.
• W2009367105 countsByYear W20093671052016 @default.
• W2009367105 countsByYear W20093671052017 @default.
• W2009367105 countsByYear W20093671052018 @default.
• W2009367105 countsByYear W20093671052019 @default.
• W2009367105 countsByYear W20093671052020 @default.
• W2009367105 countsByYear W20093671052021 @default.
• W2009367105 countsByYear W20093671052022 @default.
• W2009367105 countsByYear W20093671052023 @default.
• W2009367105 crossrefType "journal-article" @default.
• W2009367105 hasAuthorship W2009367105A5000572878 @default.
• W2009367105 hasBestOaLocation W20093671051 @default.
• W2009367105 hasConcept C120665830 @default.
• W2009367105 hasConcept C121332964 @default.
• W2009367105 hasConcept C126322002 @default.
• W2009367105 hasConcept C16005928 @default.
• W2009367105 hasConcept C17991360 @default.
• W2009367105 hasConcept C191897082 @default.
• W2009367105 hasConcept C192562407 @default.
• W2009367105 hasConcept C197934379 @default.
• W2009367105 hasConcept C2776260265 @default.
• W2009367105 hasConcept C2777138892 @default.
• W2009367105 hasConcept C2777852167 @default.
• W2009367105 hasConcept C2778758164 @default.
• W2009367105 hasConcept C2780158451 @default.
• W2009367105 hasConcept C2780564577 @default.
• W2009367105 hasConcept C61511704 @default.
• W2009367105 hasConcept C71924100 @default.
• W2009367105 hasConceptScore W2009367105C120665830 @default.
• W2009367105 hasConceptScore W2009367105C121332964 @default.
• W2009367105 hasConceptScore W2009367105C126322002 @default.
• W2009367105 hasConceptScore W2009367105C16005928 @default.
• W2009367105 hasConceptScore W2009367105C17991360 @default.
• W2009367105 hasConceptScore W2009367105C191897082 @default.
• W2009367105 hasConceptScore W2009367105C192562407 @default.
• W2009367105 hasConceptScore W2009367105C197934379 @default.
• W2009367105 hasConceptScore W2009367105C2776260265 @default.
• W2009367105 hasConceptScore W2009367105C2777138892 @default.
• W2009367105 hasConceptScore W2009367105C2777852167 @default.
• W2009367105 hasConceptScore W2009367105C2778758164 @default.
• W2009367105 hasConceptScore W2009367105C2780158451 @default.
• W2009367105 hasConceptScore W2009367105C2780564577 @default.
• W2009367105 hasConceptScore W2009367105C61511704 @default.
• W2009367105 hasConceptScore W2009367105C71924100 @default.
• W2009367105 hasIssue "s1" @default.
• W2009367105 hasLocation W20093671051 @default.
• W2009367105 hasLocation W20093671052 @default.
• W2009367105 hasOpenAccess W2009367105 @default.
• W2009367105 hasPrimaryLocation W20093671051 @default.
• W2009367105 hasRelatedWork W1884104022 @default.
• W2009367105 hasRelatedWork W1968880278 @default.
• W2009367105 hasRelatedWork W2067688080 @default.

• next